NBIXNEUROCRINE BIOSCIENCES INC
Biological Products, (no Diagnostic Substances)
- Revenue
- $2.9B
- 21% YoY
- Operating margin
- 21.6%
- 11% YoY
- EBITDA
- $645M
- 8.6% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear164% of net incomeCash flow under 80% of net income
- Dilutive SBCClear8% of revenueOver 10% of revenue
- Payouts exceed cash flowClear21% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear9% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $1.1B | $1.5B | $1.9B | $2.4B | $2.9B | 21% |
| Operating income | $103M | $249M | $251M | $571M | $619M | 8.5% |
| Net income | $90M | $155M | $250M | $341M | $479M | 40% |
| Operating cash flow | $257M | $339M | $390M | $595M | $783M | 31% |
| Capex | $23M | $17M | $28M | $38M | $34M | 11% |
| Stock-based comp | $134M | $173M | $194M | $196M | $218M | 11% |
| Buybacks | — | $0 | $0 | $300M | $168M | 44% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $826K · 3
- Net
- −$826K
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $7M | $6M | 148 | 125 |
| FY2024 | — | — | 142 | 93 |
| FY2023 | — | — | 137 | 94 |
| FY2022 | — | — | 125 | 90 |
| FY2021 | — | — | 89 | 100 |